Drug suppresses HIV
An ongoing study of 58 protease inhibitor-experienced patients suggests ABT/378/r, an advanced-generation protease inhibitor from Abbott Laboratories in Abbott Park, IL, suppresses HIV levels in 84% of patients after 48 weeks of treatment. Other findings include:
• Sixty-four percent of patients had at least a fourfold loss in susceptibility to previous protease inhibitors.
• Of 11 patients with greater than a fourfold reduced viral susceptibility to ABT-378/r at baseline, seven had a viral load of less than 400 copies/ mL at week 48 and one had a viral load less than 400 copies/mL at last visit.
"These early data suggest that ABT-378/r may have activity against drug-resistant virus," notes Steven Deeks, MD, assistant clinical professor of medicine at the University of California, San Francisco, and an investigator in the study.
For more details, see www.abbott.com.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content